10,000 adults to be tracked for RSV – could pave way for vaccine decisions
NCT ID NCT07321314
First seen Jun 27, 2026 · Last updated Sep 02, 2026 · Updated 2 times
Summary
This study will track 10,000 adults in Hong Kong with respiratory symptoms to measure how often RSV causes illness and how severe it gets. Researchers will collect nose and throat samples and blood tests over several weeks. The goal is to fill knowledge gaps about RSV in adults and help guide future vaccine use.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could provide crucial data on how common and severe RSV is in adults, helping health officials decide whether to fund vaccines for high-risk groups.
- What could go wrong
- This is an observational study, not a treatment trial. It will not test any therapy or vaccine, so it cannot directly improve health. Results depend on accurate reporting and may not apply to other regions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 10,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2026
- Expected to finish
-
Aug 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients hospitalized for community-acquired respiratory tract infection symptoms
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Community-acquired respiratory tract infection symptoms * Age \>= 18 Exclusion Criteria: * Unable to provide a good quality of sputum and saliva
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RSV are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Chinese University of Hong Kong
RECRUITINGHong Kong, Hong Kong
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new model help botswana shield infants from RSV?
- Can a simple breath test catch flu in High-HIV regions?
- Scientists deliberately infect older adults with RSV to unlock immune secrets
- Could vitamin d levels predict wheezing after bronchiolitis?
- New pill could help babies fight RSV faster
- Could a simple vaccine slash COPD attacks?